Medical and Pharmacy Cost and Utilization Outcomes of a Quantity Limit on the 5-HT1 Agonists (Triptans) by a Managed Care Organization

were analyzed during the same time periods. RESULTS: The quantity limit resulted in an overall drug and medical cost savings of $420,754 during the six months after initiation of the program. The utilization and costs associated with the triptans and other analgesic medications decreased, while the percentage of patients taking prophylactic therapy increased. A small change in utilization and costs of hospitalizations, PCP visits, ER visits, and neurologist visits was noted.